Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

AI eye scans reveal who may be at higher risk of osteoporosis

17

May 2026

AI eye scans reveal who may be at higher risk of osteoporosis

RetiAGE, an AI-derived retinal biological age score, was associated with lower bone mineral density and higher fracture risk scores in older Singaporean adults. In the UK Biobank, older retinal biological age also predicted future osteoporosis, suggesting routine retinal imaging could eventually support opportunistic osteoporosis risk screening.

AI eye scans reveal who may be at higher risk of osteoporosis

17

May 2026

AI eye scans reveal who may be at higher risk of osteoporosis

RetiAGE, an AI-derived retinal biological age score, was associated with lower bone mineral density and higher fracture risk scores in older Singaporean adults. In the UK Biobank, older retinal biological age also predicted future osteoporosis, suggesting routine retinal imaging could eventually support opportunistic osteoporosis risk screening.

AI eye scans reveal who may be at higher risk of osteoporosis

17

May 2026

AI eye scans reveal who may be at higher risk of osteoporosis

RetiAGE, an AI-derived retinal biological age score, was associated with lower bone mineral density and higher fracture risk scores in older Singaporean adults. In the UK Biobank, older retinal biological age also predicted future osteoporosis, suggesting routine retinal imaging could eventually support opportunistic osteoporosis risk screening.

AI eye scans reveal who may be at higher risk of osteoporosis

17

May 2026

AI eye scans reveal who may be at higher risk of osteoporosis

RetiAGE, an AI-derived retinal biological age score, was associated with lower bone mineral density and higher fracture risk scores in older Singaporean adults. In the UK Biobank, older retinal biological age also predicted future osteoporosis, suggesting routine retinal imaging could eventually support opportunistic osteoporosis risk screening.

AI beats primary care doctors in simulated diagnosis study using images and ECGs

17

May 2026

AI beats primary care doctors in simulated diagnosis study using images and ECGs

Multi-modal AMIE used state-aware reasoning to interpret patient history alongside skin photos, ECGs, and clinical documents during simulated telehealth consultations. In a blinded exploratory OSCE-style study, AMIE outperformed primary care physicians across most diagnostic, communication, empathy, and multimodal reasoning measures, but still requires real-world clinical validation.

Prenatal chemical mixtures may influence fetal growth and placental health

17

May 2026

Prenatal chemical mixtures may influence fetal growth and placental health

Common environmental chemicals could affect birthweight and placental function, according to a new study published in Environmental Science & Technology and led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa" Foundation. Conducted within the Barcelona Life Study Cohort (BiSC), the research underscores the importance of considering real-life exposure to complex chemical mixtures and highlights the role of angiogenic biomarkers in linking these exposures to fetal development.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.